TACARYL Drug Patent Profile

When do Tacaryl patents expire, and when can generic versions of Tacaryl launch?

Tacaryl is a drug marketed by Westwood Squibb and is included in one NDA.

The generic ingredient in TACARYL is methdilazine. There are four drug master file entries for this compound. Additional details are available on the methdilazine profile page.

Summary for TACARYL

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for TACARYL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Westwood Squibb	TACARYL	methdilazine hydrochloride	SYRUP;ORAL	011950-007	Approved Prior to Jan 1, 1982		DISCN	No	No
Westwood Squibb	TACARYL	methdilazine	TABLET, CHEWABLE;ORAL	011950-009	Approved Prior to Jan 1, 1982		DISCN	No	No
Westwood Squibb	TACARYL	methdilazine hydrochloride	TABLET;ORAL	011950-006	Approved Prior to Jan 1, 1982		DISCN	No	No

TACARYL: Competitive Landscape and Patent Exclusivity Analysis

Last updated: February 17, 2026

TACARYL (brand name for Nebivolol), a beta-blocker used to treat hypertension, faces a mature market with significant generic competition. Its primary patent protection has expired in key markets, impacting market exclusivity and pricing power. The drug's efficacy in specific patient populations and its established safety profile remain key differentiators, but new entrants and alternative therapies pose ongoing challenges.

What is the Mechanism of Action and Therapeutic Use of TACARYL?

TACARYL is a beta-adrenergic receptor antagonist. Specifically, it selectively blocks beta-1 adrenergic receptors located in the heart. This blockade results in a decrease in heart rate, myocardial contractility, and blood pressure. TACARYL also exhibits vasodilatory properties mediated by the nitric oxide pathway, which further contributes to its antihypertensive effect.

The primary therapeutic indication for TACARYL is the treatment of essential hypertension in adult patients. It is used as monotherapy or in combination with other antihypertensive agents [1].

What are the Key Patents Protecting TACARYL?

The foundational patent for Nebivolol, U.S. Patent No. 4,654,364, was filed on October 15, 1984, and issued on March 3, 1987. This patent provided composition of matter protection. It has long since expired.

Subsequent patents focused on specific formulations, methods of use, and manufacturing processes. For instance, U.S. Patent No. 5,948,788, related to a specific crystalline form of Nebivolol hydrochloride, was issued in 1999. However, these later-generation patents have also expired or are nearing expiration in major markets.

A critical aspect of Nebivolol's patent history involved challenges to its market exclusivity. The U.S. Food and Drug Administration (FDA) Orange Book lists patent information for approved drugs. For Nebivolol hydrochloride (brand name Bystolic), the listed patents include the '364 patent (expired) and others related to formulations and methods of use, most of which have also expired [2].

The patent expiry dates are crucial for understanding market dynamics:

• U.S. Patent No. 4,654,364: Expired March 3, 2007 (Original term).
• U.S. Patent No. 5,948,788: Expired September 7, 2019 (Original term).
• Pediatric Exclusivity: For Nebivolol, pediatric exclusivity was granted, extending protection to September 7, 2020. This granted an additional six months of market exclusivity for the approved pediatric indication, which was later withdrawn [3].

The expiration of these key patents has allowed for the introduction of generic versions of Nebivolol into the market.

What is the Current Market Landscape for Nebivolol?

The market for Nebivolol is characterized by the presence of generic competitors. Following the expiration of primary patent protections, multiple pharmaceutical companies have launched generic Nebivolol products. This has led to a significant decrease in the average selling price of the drug and reduced market share for the branded product, Bystolic.

Key aspects of the current market landscape include:

• Generic Entry: The introduction of generics began in earnest following the expiration of key patents. Companies like Teva Pharmaceuticals, Mylan (now Viatris), and Aurobindo Pharma have been among the active generic manufacturers [4].
• Price Erosion: The competitive pressure from generics has resulted in substantial price erosion. Branded Nebivolol prices have declined by over 80% in some segments compared to pre-generic entry levels.
• Market Share Shift: The branded product's market share has diminished considerably, with generics now holding the dominant position in terms of prescription volume.
• Therapeutic Class Competition: Nebivolol competes within the broader class of beta-blockers, which includes established and widely prescribed agents such as metoprolol, atenolol, and carvedilol. It also faces competition from other antihypertensive drug classes, including ACE inhibitors, ARBs, calcium channel blockers, and diuretics.
• Physician Prescribing Patterns: While generic substitution is common, some physicians may continue to prescribe the branded product for specific patient populations or based on established clinical experience. However, the cost-effectiveness of generics generally favors their widespread adoption.

How Does TACARYL's Patent Exclusivity Compare to Competitors?

Nebivolol's patent exclusivity timeline is relatively mature compared to newer antihypertensive agents.

Drug Class	Example Drug(s)	Primary Patent Type	Approximate Expiry (US)	Current Status
Beta-Blockers	Nebivolol (TACARYL)	Composition of Matter	2007	Generic competition active
	Metoprolol Succinate	Composition of Matter	2004	Generic competition active
	Carvedilol	Composition of Matter	2007	Generic competition active
Angiotensin Receptor Blockers	Losartan	Composition of Matter	2010	Generic competition active
	Valsartan	Composition of Matter	2014	Generic competition active
	Olmesartan	Composition of Matter	2016	Generic competition active
Angiotensin-Converting Enzyme Inhibitors	Lisinopril	Composition of Matter	2008	Generic competition active
	Enalapril	Composition of Matter	2002	Generic competition active
Newer Antihypertensives	Sacubitril/Valsartan (Entresto)	Composition of Matter	2027 (with extensions)	Branded exclusivity ongoing
	Empagliflozin (Jardiance) - Cardiovascular benefits	Composition of Matter	2025 (with extensions)	Branded exclusivity ongoing

Note: Patent expiry dates can be complex due to extensions, inter partes reviews, and market-specific regulations. The dates provided are approximate for primary composition of matter patents.

This comparison highlights that Nebivolol, like many older beta-blockers, has already navigated its primary patent cliff. Newer drugs targeting cardiovascular disease, particularly those with novel mechanisms or demonstrated benefits in cardiorenal outcomes (like SGLT2 inhibitors for heart failure), generally have longer periods of patent-protected market exclusivity.

What are the Regulatory Status and Market Approvals for TACARYL?

Nebivolol is approved by major regulatory agencies worldwide for the treatment of hypertension.

• United States: Approved by the Food and Drug Administration (FDA). The branded product, Bystolic, was initially approved in December 2007. Generic versions are now widely available [5].
• European Union: Approved by the European Medicines Agency (EMA). The brand name is typically Nebilet. Marketing authorizations are held by various national agencies within the EU.
• Other Markets: Nebivolol has also received approval in Canada, Australia, Japan, and numerous other countries.

The regulatory landscape is stable for the approved indications. However, the long-term outlook is influenced by the availability of generics and the evolving treatment guidelines for hypertension, which increasingly emphasize combination therapies and outcome-based evidence.

What are the Key Economic Factors and Market Projections for Nebivolol?

The economic factors for Nebivolol are primarily driven by the transition to a genericized market.

• Sales Trajectory: Post-patent expiry, sales of branded Nebivolol have significantly declined. The market is now dominated by generic sales, which are characterized by lower unit prices and high volume.
• Market Size: The global market for Nebivolol, considering both branded and generic forms, is substantial due to the high prevalence of hypertension. However, the revenue generated is increasingly fragmented among generic manufacturers.
• Pricing: Generic Nebivolol is priced competitively. The average wholesale price (AWP) for generic Nebivolol is a fraction of the historical AWP for branded Bystolic. This price differential is a key driver for generic adoption.
• Market Projections: The market for Nebivolol is projected to remain stable in terms of volume, driven by its established therapeutic profile and physician familiarity. However, revenue growth is unlikely for the branded product, and the overall market revenue is expected to be driven by volume increases in generic sales rather than price appreciation. The market is highly price-sensitive.

What are the Potential Opportunities and Threats for Nebivolol Stakeholders?

Stakeholders in the Nebivolol market face a mix of opportunities and threats.

Opportunities:

• Global Market Expansion (Generics): For generic manufacturers, opportunities exist in expanding market reach in emerging economies where generic penetration is growing and healthcare access is increasing.
• Combination Therapies: While Nebivolol is approved as monotherapy, there is potential for its inclusion in fixed-dose combination products with other antihypertensive agents, provided clear clinical benefits and favorable patent/regulatory pathways exist. However, with generic Nebivolol widely available, the incentive for developing new branded combinations solely featuring Nebivolol is diminished.
• Specific Patient Populations: Nebivolol's unique vasodilatory properties may offer specific advantages in certain patient subgroups, potentially supporting its continued use and niche market share even in a generic environment.

Threats:

• Intense Generic Competition: The primary threat is the highly competitive generic market, leading to continuous price pressure and margin compression for all participants.
• Evolving Treatment Guidelines: Hypertension treatment guidelines are dynamic, emphasizing combination therapies and drugs with proven cardiovascular and renal outcome benefits. Newer drug classes or agents with superior evidence profiles may displace older generics.
• New Drug Development: Continued research and development in the cardiovascular space may yield novel antihypertensive agents with improved efficacy, safety, or tolerability, potentially reducing the market share of existing drugs like Nebivolol.
• Regulatory Scrutiny: While Nebivolol is well-established, any future safety concerns or adverse event reports could lead to label changes or restrictions, impacting its market position.
• Cost Containment Pressures: Healthcare systems globally are under increasing pressure to control costs, which further favors the use of lower-cost generic medications.

Key Takeaways

TACARYL (Nebivolol) operates in a post-patent exclusivity market, primarily characterized by widespread generic competition. The drug's original composition of matter patents have expired, along with most subsequent formulation and method-of-use patents, enabling the entry and proliferation of generic versions. This has led to significant price erosion and a shift in market share away from the branded product. While Nebivolol retains its therapeutic value due to its mechanism of action and established safety profile, particularly its vasodilatory properties, it faces intense competition from other beta-blockers and a broad spectrum of alternative antihypertensive drug classes. Future market dynamics will be dictated by generic pricing strategies, evolving treatment guidelines, and the development of novel cardiovascular therapies.

Frequently Asked Questions

1. When did the primary patent for Nebivolol expire in the United States? The U.S. patent for Nebivolol's composition of matter, U.S. Patent No. 4,654,364, expired on March 3, 2007.

2. Has Nebivolol received any pediatric exclusivity extensions, and did they remain in effect? Yes, Nebivolol received pediatric exclusivity, which initially extended market protection to September 7, 2020. However, this indication was later withdrawn, impacting the practical benefit of that extension.

3. What are the main therapeutic advantages of Nebivolol compared to other beta-blockers? Nebivolol's main advantage is its dual mechanism of action: selective beta-1 blockade and nitric oxide-mediated vasodilation, which contributes to blood pressure reduction with potentially fewer side effects compared to some older beta-blockers.

4. Can new patents be filed for Nebivolol, and would they grant market exclusivity? While new patents can be filed for novel formulations, delivery systems, or methods of use, these would typically receive a shorter period of exclusivity (e.g., 5 years in the U.S. for new formulations) compared to the original composition of matter patent and would not prevent generic competition for the original approved indication.

5. What is the current competitive status of Nebivolol in the global antihypertensive market? Nebivolol is now largely considered a mature, genericized drug within the global antihypertensive market, competing primarily on price and established clinical practice against a wide array of branded and generic alternatives.

Citations

[1] Lexicomp. (n.d.). Nebivolol. Retrieved from Lexicomp Online database.

[2] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-approved-drug-products-therapeutic-equivalence-evaluations

[3] U.S. Food and Drug Administration. (2015, September 7). FDA Announces Withdrawal of Approval for pediatric use of Bystolic (nebivolol) tablets. FDA News Release.

[4] Various generic drug manufacturers' product information and financial reports (e.g., Teva Pharmaceuticals, Viatris, Aurobindo Pharma).

[5] U.S. Food and Drug Administration. (n.d.). Drug Approval Packages. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approval-packages